Genetic modulation of the pharmacological treatment of pain.
about
Bitterness of the non-nutritive sweetener acesulfame potassium varies with polymorphisms in TAS2R9 and TAS2R31Personalized medicine and opioid analgesic prescribing for chronic pain: opportunities and challengesGene-to-gene interactions regulate endogenous pain modulation in fibromyalgia patients and healthy controls-antagonistic effects between opioid and serotonin-related genes.Clinical pharmacology of analgesic medicines in older people: impact of frailty and cognitive impairmentClinical and genetic factors related to cancer-induced bone pain and bone pain relief.Drug response profiles to experimental pain are opioid and pain modality specificAssociation of polymorphisms in pharmacogenetic candidate genes (OPRD1, GAL, ABCB1, OPRM1) with opioid dependence in European population: a case-control study.Pharmacogenetics of new analgesics.Genomics and pain research in sickle cell disease: an explanation of heterogeneity?Polymorphism of the Glutamate Transporter Protein EAAT2 and Migraine Transformation into Chronic Daily Headache.Epigenetics and the transition from acute to chronic pain.Impaired behavioural pain responses in hph-1 mice with inherited deficiency in GTP cyclohydrolase 1 in models of inflammatory pain.Personalized therapy in pain management: where do we stand?Epigenetics in pain and analgesia: an imminent research field.Genetic variability of pain perception and treatment--clinical pharmacological implications.Pain management in patients with cancer: focus on opioid analgesics.Pain, analgesia and genetics.Pharmacogenetics of pain and analgesia.Challenges in pharmacogenetics.Population pharmacokinetic-pharmacodynamic modeling of ketamine-induced pain relief of chronic pain.Prospective replication study implicates the catechol-O-methyltransferase Val158Met polymorphism as a biomarker for the response to morphine in patients with cancer.Opioid management and dependency among adult patients with sickle cell disease.Micro opioid receptor A118G polymorphism and post-operative pain: opioids' effects on heterozygous patients.Genotyping the Mu-opioid receptor A118G polymorphism using the real-time amplification refractory mutation system: allele frequency distribution among Brazilians.Non-invasive combined surrogates of remifentanil blood concentrations with relevance to analgesia.Genetic variability at COMT but not at OPRM1 and UGT2B7 loci modulates morphine analgesic response in acute postoperative pain.Genome-wide association study identifies candidate loci associated with postoperative fentanyl requirements after laparoscopic-assisted colectomy.Widespread pain in temporomandibular disorders.Serum concentrations of opioids when comparing two switching strategies to methadone for cancer pain.Genome-wide scan identifies candidate loci related to remifentanil requirements during laparoscopic-assisted colectomy.Development of an AmpliSeq Panel for Next-Generation Sequencing of a Set of Genetic Predictors of Persisting Pain
P2860
Q24624278-7C7623E8-F9AF-49CD-B819-167DC7B278CDQ24627422-7E498DB4-E311-4590-9930-99E8B6A9A1D5Q33802439-F40A7B83-CF2D-4411-BE17-CD7ABC718E11Q34608990-C3E7E14D-6A3E-46FF-8314-D3348E276C36Q34641014-60F67D90-1FA1-4DD2-978A-F29500A6D3B0Q34644376-770A52C4-8F10-4744-9324-B68C5E6C8D04Q35005588-05D8C81D-0193-43D0-8B35-BBED99BEFC58Q35005640-DF9E7083-290A-4841-8CED-674B71E80CB9Q35137080-E47E0DEB-5D68-46EC-AE19-AD539FF961AFQ35539662-307FB45E-FCDF-4DB7-B4D3-E10CA5970E35Q36409626-14F8053F-EFA4-4D1E-8185-70F795AA70D6Q36767434-F15C2355-9D2B-4E1D-8EB7-CFC3AE8E5695Q37760955-C77F4F3B-7B7B-448C-A1AF-7C9DC5F790DDQ37768267-B030DB63-6AEC-4CC2-9223-78FE0FE388B3Q37846139-F22E5289-AE4D-453D-BEF8-0BB015E8B19FQ37863588-B19A07C8-AE72-4A09-81E3-3DA2B27A4241Q37944353-5A3B2A7A-5415-4ED8-B2DF-57FD18302230Q38025139-B527CF06-FBDD-4263-9813-D48BF7D73AA9Q38103767-78D7874C-61EA-4676-A589-18A6903C3FCDQ39282857-C155550D-77B6-42CE-B928-58E41FDC5098Q41530676-ADDC8A63-1BFF-45B9-BA4F-1B47D66628BAQ44330594-529CA18C-2B99-45BD-B658-B0BE67CF55B0Q44332403-283BB56F-D9F0-448A-BA45-6DD9CA424118Q44338042-1B29171F-7955-491F-A1CF-43B7F0DF5024Q46052967-206D4B38-2175-4ED5-B8F6-340DAC52018DQ46122578-D98AEAB8-68F7-4BAF-A6A7-993E4D89C008Q47627820-59FBED8A-80BD-4C59-8602-A4AFFE11EFCDQ48315186-C82F02B6-C901-42B0-95A4-2703A8205FE6Q48721652-7EF21633-FAD9-419D-9BD1-7570ADC04F5EQ50061993-A69AA8FD-7667-46AB-9997-44585BF8CD00Q57072929-C6ACA2F7-4938-4D8F-8A04-F1C97DA7511B
P2860
Genetic modulation of the pharmacological treatment of pain.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 15 July 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Genetic modulation of the pharmacological treatment of pain.
@en
Genetic modulation of the pharmacological treatment of pain.
@nl
type
label
Genetic modulation of the pharmacological treatment of pain.
@en
Genetic modulation of the pharmacological treatment of pain.
@nl
prefLabel
Genetic modulation of the pharmacological treatment of pain.
@en
Genetic modulation of the pharmacological treatment of pain.
@nl
P1476
Genetic modulation of the pharmacological treatment of pain.
@en
P2093
Gerd Geisslinger
P304
P356
10.1016/J.PHARMTHERA.2009.06.010
P577
2009-07-15T00:00:00Z